KL-1156

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 562699

CAS#: 819868-62-7

Description: KL-1156 is a NF-κB inhibitor and lipopolysaccharide (LPS)-induced nitric oxide production inhibitor.

Chemical Structure

img
KL-1156
CAS# 819868-62-7
Instruction

Theoretical Analysis

MedKoo Cat#: 562699
Name: KL-1156
CAS#: 819868-62-7
Chemical Formula: C17H17NO4
Exact Mass: 299.12
Molecular Weight: 299.320
Elemental Analysis: C, 68.22; H, 5.72; N, 4.68; O, 21.38

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: KL-1156; KL 1156; KL1156;

IUPAC/Chemical Name: 6-Hydroxy-7-methoxy-N-phenyl-3,4-dihydro-2H-chromene-2-carboxamide

InChi Key: JXCMRGWJFGLXJJ-UHFFFAOYSA-N

InChi Code: InChI=1S/C17H17NO4/c1-21-16-10-15-11(9-13(16)19)7-8-14(22-15)17(20)18-12-5-3-2-4-6-12/h2-6,9-10,14,19H,7-8H2,1H3,(H,18,20)

SMILES Code: O=C(C1CCC2=C(O1)C=C(OC)C(O)=C2)NC3=CC=CC=C3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 299.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Choi M, Jo H, Park HJ, Sateesh Kumar A, Lee J, Yun J, Kim Y, Han SB, Jung JK, Cho J, Lee K, Kwak JH, Lee H. Design, synthesis, and biological evaluation of benzofuran- and 2,3-dihydrobenzofuran-2-carboxylic acid N-(substituted)phenylamide derivatives as anticancer agents and inhibitors of NF-κB. Bioorg Med Chem Lett. 2015 Jun 15;25(12):2545-9. doi: 10.1016/j.bmcl.2015.04.050. Epub 2015 Apr 23. PubMed PMID: 25953156.

2: Choi M, Hwang YS, Kumar AS, Jo H, Jeong Y, Oh Y, Lee J, Yun J, Kim Y, Han SB, Jung JK, Cho J, Lee H. Design and synthesis of 3,4-dihydro-2H-benzo[h]chromene derivatives as potential NF-κB inhibitors. Bioorg Med Chem Lett. 2014 Jun 1;24(11):2404-7. doi: 10.1016/j.bmcl.2014.04.053. Epub 2014 Apr 20. PubMed PMID: 24792464.

3: Kwak JH, Won SW, Kim TJ, Yi W, Choi EH, Kim SC, Park H, Roh E, Jung JK, Hwang BY, Hong JT, Kim Y, Cho J, Lee H. Synthesis and nuclear factor-kappaB inhibitory activities of 6- or 7-methylchroman-2-carboxylic acid N-(substituted) phenylamides. Arch Pharm Res. 2009 Feb;32(2):167-75. doi: 10.1007/s12272-009-1131-3. Epub 2009 Mar 13. PubMed PMID: 19280144.

4: Kwak JH, Won SW, Kim TJ, Roh E, Kang HY, Lee HW, Jung JK, Hwang BY, Kim Y, Cho J, Lee H. Synthesis of chroman-2-carboxylic acid N-(substituted)phenylamides and their inhibitory effect on nuclear factor-kappaB (NF-kappaB) activation. Arch Pharm Res. 2008 Feb;31(2):133-41. PubMed PMID: 18365680.

5: Kwak JH, Kim BH, Jung JK, Kim Y, Cho J, Lee H. Structure-activity relationships of 6-hydroxy-7-methoxychroman-2-carboxylic acid N-(substituted)phenylamides as inhibitors of nuclear factor-kappaB activation. Arch Pharm Res. 2007 Oct;30(10):1210-5. PubMed PMID: 18038899.

6: Rak Min K, Lee H, Hak Kim B, Chung E, Min Cho S, Kim Y. Inhibitory effect of 6-hydroxy-7-methoxychroman-2-carboxylic acid phenylamide on nitric oxide and interleukin-6 production in macrophages. Life Sci. 2005 Nov 4;77(25):3242-57. Epub 2005 Jun 22. PubMed PMID: 15978634.

7: Kim BH, Reddy AM, Lee KH, Chung EY, Cho SM, Lee H, Min KR, Kim Y. Inhibitory mechanism of chroman compound on LPS-induced nitric oxide production and nuclear factor-kappaB activation. Biochem Biophys Res Commun. 2004 Dec 3;325(1):223-8. PubMed PMID: 15522222.